Tomahawk, WI 06/19/2014 (Basicsmedia) – Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG), a bio-pharmaceutical company focused on developing and discovering novel small-molecule oncology therapeutics, has two products in its pipeline – Birinapant and SHAPE.

$47 Million Offering

On June 17, TLOG announced that it is all set to offer principal amount of $47 million and 8% of legally convertible notes due 2019, in an extensive private offering. The offer shall be sold to a host of institutional buyers, following the Rule 144A, under the amended Securities Act (1933).

TLOG confirmed that the notes shall be Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG)’s unsubordinated and unsecured obligations, and shall warrant the right of payment pertaining to the company’s indebtedness. The notes can be used to clear the company’s unsubordinated unsecured liabilities and instances of indebtedness at the current juncture and in the future. The caveat applies directly to clear the liabilities concerned, pertaining to current and future indebtedness of TLOG and its subsidiaries.

Rules And Norms

TLOG confirmed in its release that the notes shall bear 8.00% interest per annum, payable solely in cash, on the 15th of June and December each year, semi-annually. The notes shall be convertible holistically, without any iota of deduction, before February 2019. On account of precedent ‘fundamental changes’, the holders would have right to completely purchase part of their own notes in the form of cash reserves, paying or delivering 100% of fixed principal amount pertaining to the notes purchased, without accrued interest levied.

TLOG Hopes To Notch Up $44 Million As Proceeds

TLOG conjectured that these net proceeds from this exquisite offering, shall evaluate to $44 million, post-deduction of individual purchasers’ commissions or discounts. A company-source corroborated that the proceeds shall be utilized for offering preclinical and clinical development activities for SuberoHydroxamic Acid Phenyl Ester, dubbed SHAPE, or Birinapant. This offer shall end on June 23.

Products In Pipeline

Birinapant is currently undergoing its Phase 1 test and Phase 2 trial for solid tumors and hematological malignancies, whereas SHAPE, which deals in treatment of cutaneous T-cell lymphoma, has entered into Phase 2 trials. Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG) hopes to generate greater working capital by acquire sumptuous proceeds from this offering, for bolstered in-licensing opportunities and general corporate purpose.

DISCLAIMER: This content is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.